Dallas, Texas (PRWEB) September 10, 2014
Epidemiologists forecast that the number of diagnosed incident cases of breast cancer in women in the 8MM is expected to grow to 1.21 million cases in 2023 at a rate of 4.23% per year during the forecast period. The number of five-year diagnosed prevalent cases in the 8MM is expected to increase by 43.0% over the next decade to 5.12 million cases in 2023.
Breast cancer is a malignant tumor that originates in the breast tissues. Most breast cancers are invasive tumors that have grown beyond the ducts or lobules of the breast and can metastasize to other parts of the body through the bloodstream and the lymphatic system. Prolonged exposure to endogenous and exogenous sex hormones, gene mutations, a family history of breast cancer, overweight and obesity, physical inactivity, a sedentary lifestyle, high alcohol consumption, early age at menarche (less than 12 years), late age at menopause (Greater Than 55 years), and clinical factors, such as biopsy-confirmed atypical hyperplasia, and having a high breast tissue and bone density are all risk factors for breast cancer.
Complete Report Details Available @ http://www.marketoptimizer.org/epicast-report-breast-cancer-her2-her2-epidemiology-forecast-to-2023.html .
Forecast is supported by at least 10 years of robust, country-specific historical data obtained from the WHO International Agency for Cancer Research’s (IARC’s) SurvCan, the Surveillance of Epidemiology and End Results Program Cancer Statistics Review 1975-2009, EUROCARE-4, research articles published in peer-reviewed journals, and the IARC’s Cancer Incidence in Five Continents Plus database, which provided detailed case segmentation by age and sex and is considered the gold standard for international comparison of country-specific data. Strength of this analysis is that epidemiologists compared the incident case projections with the estimates made by country-specific registries and the IARC, and found that the forecast numbers were in accordance with the international estimates.
- The Breast Cancer (HER2-, HER2+) EpiCast Report and EpiCast Model provide an overview of the risk factors, comorbidities, and the global and historical trends for breast cancer in the eight major markets (8MM) (US, France, Germany, Italy, Spain, UK, Japan, and urban China). In addition, the report also includes a 10-year forecast for the incident and the five-year prevalent cases of breast cancer in women segmented by age (20 to =85 years), natural menopausal status, cancer stage at diagnosis (local, regional, distant, unstaged), and hormone receptor subtypes: ER+ and/or PR+, HER2-; ER-, PR-, HER2+; ER+ and /or PR+, HER2+; and ER-, PR-, HER2- (triple negative).
- The breast cancer epidemiology report and model were written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.
- The EpiCast Model is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.
Order a Purchase Copy @ http://www.marketoptimizer.org/contacts/purchase?rname=10411 .
Reasons to Buy
- Develop business strategies by understanding the trends shaping and driving the global breast cancer market.
- Quantify patient populations in the global breast cancer market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups, menopausal status, cancer stage, and hormone receptor subtypes that present the best opportunities for breast cancer therapeutics in each of the markets covered.
Major Points in Table of Contents
4.1 Disease Background
4.2 Risk Factors and Comorbidities
4.2.1 A family history of breast cancer and BRCA1/2 gene mutations significantly increase the breast cancer risk
4.2.2 Reproductive hormonal factors influence the risk of breast cancer
4.2.3 Modifiable lifestyle-related factors increase the risk of mortality in breast cancer patients
4.2.4 Screening programs have been shown to reduce breast cancer mortality, although the benefits need to be carefully weighed against the risks
4.3 Global Trends
4.3.2 Prevalence and Survival
4.4 Forecast Methodology
4.4.1 Sources Used
4.4.2 Sources Not Used
4.4.3 Forecast Assumptions and Methods
4.5 Epidemiological Forecast for Breast Cancer (2013–2023) – Diagnosed Incident Cases
4.5.1 Diagnosed Incident Cases of Breast Cancer
4.5.2 Diagnosed Incident Cases of Breast Cancer by Age
4.5.3 Diagnosed Incident Cases of Breast Cancer by Menopausal Status
4.5.4 Diagnosed Incident Cases of Breast Cancer Segmented by Stage at Diagnosis
4.5.5 Age-Standardized Diagnosed Incidence Rate of Breast Cancer
4.6 Epidemiological Forecast for Breast Cancer (2013–2023) — Diagnosed Prevalent Cases
4.6.1 Five-Year Diagnosed Prevalent Cases of Breast Cancer
4.6.2 Five-Year Diagnosed Prevalent Cases by Menopausal Status
4.6.3 Five-Year Diagnosed Prevalent Cases by Hormone Receptor Subtypes
Explore more reports on Pharmaceuticals industry at http://www.marketoptimizer.org/category/life-sciences/pharmaceuticals .
MarketOptimizer.org is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.